BXTAccelyon Blog

February 16, 2017

The ASCENDE-RT (Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy) study was the first randomized clinical trial comparing brachytherapy to the traditional use of external beam radiation therapy to treat intermediate and high risk Prostate Cancer patients over a period of between 6 to 9 years. The results show a significant increase in survival rates with an average of 50% of patients showing progression free survival when treated with LDR brachytherapy.

December 10, 2016

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, according to research presented at the 58th Annual Meeting the American Society for Radiation Oncology (ASTRO).